epidem
ebola
viru
diseas
evd
west
africa
unpreced
scale
spread
case
count
death
toll
surpass
total
number
case
previou
known
outbreak
epidem
caus
death
case
figur
wide
thought
underestim
develop
deploy
efficaci
evd
therapeut
vaccin
could
play
signific
role
limit
outbreak
remain
prioriti
prevent
futur
evd
epidem
famili
filovirida
includ
marburg
five
ebolavirus
name
locat
recognit
zair
known
ebola
viru
ebov
sudan
sudv
reston
restv
forest
tafv
bundibugyo
viru
bdbv
singl
protein
express
surfac
filovirus
glycoprotein
gp
antigen
immunolog
import
frequent
therapeut
target
howev
bioinformat
analysi
structurebas
amino
acid
level
demarc
limit
region
homolog
gp
also
larg
area
diverg
particularli
head
domain
gp
therefor
unclear
exposur
one
member
famili
filovirida
confer
crossprotect
immun
unclear
immun
respons
involv
ebola
viru
clearanc
depend
singl
aspect
immun
system
cellular
humor
immun
multifacet
respons
prerequisit
present
clear
correl
protect
evd
indic
experiment
infect
vaccin
nonhuman
primat
suggest
role
gpspecif
igg
cell
limit
analys
convalesc
sampl
suggest
presenc
ebola
virusspecif
igg
intact
cellmedi
immun
cmi
associ
surviv
natur
infect
observ
support
immunolog
analysi
survivor
current
outbreak
indic
multifacet
respons
induc
postinfect
strong
humor
immun
significantli
pronounc
transcript
chang
cell
respons
sever
ebola
viru
protein
evd
vaccin
develop
well
establish
sinc
discoveri
ebola
viru
number
differ
vaccin
platform
use
result
least
one
efficaci
vaccin
vaccin
platform
includ
dna
recombin
subunit
protein
viruslik
particl
vlp
recombin
viral
vector
number
vaccin
advanc
past
preclin
test
undergo
clinic
test
gener
modal
demonstr
efficaci
high
level
immunogen
preclin
model
clinic
advanc
vaccin
evd
base
gener
immun
respons
toward
gp
trial
ongo
europ
usa
africa
eight
vaccin
clinic
trial
target
ebola
viru
gp
regimen
employ
singl
dose
other
use
two
vaccin
heterolog
primeboost
approach
primeboost
regimen
shown
immunogen
singledos
vaccin
diseas
malaria
howev
financi
logist
implic
associ
administ
two
vaccin
ebola
viru
vaccin
current
assess
differ
qualit
immun
respons
postvaccin
may
due
use
altern
vaccin
platform
inde
humor
immun
may
critic
protect
post
vesicular
stomat
viru
vsv
vector
vaccin
nonhuman
primat
nhp
cmi
may
key
post
singleshot
adenoviru
vector
vaccin
humor
cellular
immun
demonstr
protect
nhp
induc
man
postebov
infect
vaccin
regimen
induc
longliv
sustain
level
cmi
antibodi
desir
primarili
final
vaccin
safe
efficaci
deploy
fieldeffect
therefor
vaccin
candid
progress
publish
phase
studi
review
clinic
trial
result
publish
peerreview
journal
juli
summar
tabl
earliest
clinic
studi
vaccin
evd
use
plasmid
dna
encod
nucleoprotein
zair
ebolaviru
glycoprotein
ebov
sudv
although
well
toler
mostli
mild
shortliv
advers
event
ae
dna
vaccin
tend
poorli
immunogen
larg
superced
subunit
protein
recombin
viral
vector
vlp
sever
vaccin
develop
field
includ
ebola
viru
vaccin
progress
prevent
evd
use
viral
vector
platform
technolog
use
either
adenoviru
modifi
vaccinia
viru
ankara
vesicular
stomat
viru
backbon
recombin
human
serotyp
adenoviru
vector
encod
gp
evalu
singledos
studi
shown
accept
safeti
profil
unfortun
volunt
demonstr
statist
significantli
lower
gpspecif
igg
titr
increas
administ
dose
vaccin
appear
overcom
preexist
immun
serotyp
howev
associ
increas
reactogen
unfound
concern
also
still
persist
potenti
increas
infect
rate
among
vaccine
base
data
two
phase
ii
studi
merck
gagpolnef
vaccin
step
phambili
trial
use
rarer
serotyp
human
adenovirus
bypass
preexist
immun
demonstr
accept
safeti
toler
profil
wide
evalu
adenovir
vector
evd
vaccin
base
simian
adenoviru
serotyp
backbon
encod
either
ebolaviru
glycoprotein
alon
administ
singl
shot
mixtur
ebov
sudv
vaccin
septemb
januari
four
phase
studi
vaccin
undertaken
one
us
uk
switzerland
mali
replicationdefici
chimpanze
adenoviru
vector
extens
evalu
candid
vaccin
malaria
hiv
hcv
rsv
influenza
tuberculosi
adult
children
infant
safeti
concern
safeti
profil
similar
candid
ebola
viru
vaccin
higher
dose
elicit
ae
howev
ae
mostli
grade
mild
resolv
within
h
vaccin
addit
vaccin
modal
test
modifi
vaccinia
ankara
mva
unmodifi
recombin
mva
vector
vaccin
evalu
extens
vector
smallpox
malaria
flu
tb
vaccin
excel
safeti
demonstr
immunocompet
hivinfect
particip
preclin
trial
observ
provid
protect
nhp
challeng
ebola
viru
shortli
vaccin
howev
mva
boost
requir
enabl
uniform
protect
challeng
occur
month
prime
vaccin
increas
durabl
protect
attribut
superior
effector
memori
cell
respons
elicit
mva
boost
owe
superior
durabl
protect
demonstr
primeboost
regimen
preclin
trial
sever
phase
clinic
trial
initi
test
regimen
human
mvabn
filo
recombin
replicationdefici
mva
vector
encod
ebov
sudv
marburg
glycoprotein
well
tafv
nucleoprotein
two
clinic
trial
assess
prime
mvabn
filo
boost
demonstr
accept
safeti
profil
significantli
enhanc
cellular
humor
immunogen
compar
singleshot
vaccin
vaccin
modal
assess
ebola
vaccin
candid
recombin
vesicular
stomat
viru
encod
ebov
glycoprotein
rvsvzebov
attenu
replicationcompet
viral
vector
unmodifi
vsv
caus
either
asymptomat
infect
mild
flulik
ill
human
howev
truncat
vsv
glycoprotein
result
attenu
avirul
form
shown
safe
preclin
studi
macaqu
mice
evid
viral
shed
rvsv
gag
vaccin
also
gener
accept
safeti
data
two
phase
studi
candid
vaccin
use
vector
also
elicit
protect
ebola
marburg
virus
nhp
model
sever
rvsv
encod
singl
filoviru
glycoprotein
mix
inject
singl
dose
elicit
protect
lethal
challeng
six
phase
studi
rvsvzebov
initi
perform
octob
januari
two
us
one
kenya
gabon
switzerland
germani
almost
particip
display
transient
rvsv
viraemia
start
day
last
beyond
day
around
particip
mostli
mild
moder
ae
last
h
averag
total
particip
across
six
trial
document
fever
vaccin
significantli
higher
observ
vaccin
p
twotail
fisher
exact
prism
version
graphpad
softwar
although
vaccin
evalu
across
rang
dose
postimmun
fever
level
import
consider
vaccin
may
deploy
outbreak
highli
febril
ill
evd
geneva
trial
particip
develop
arthriti
last
median
day
viru
subsequ
identifi
synovi
joint
fluid
indic
peripher
viral
replic
two
case
shorter
durat
identifi
among
particip
studi
studi
geneva
much
lower
dose
rvsvzebov
evalu
volunt
result
much
lower
total
igg
neutral
antibodi
titr
associ
arthriti
particip
transient
arthriti
often
observ
immun
commonli
use
live
vaccin
rubella
howev
rvsvzebov
progress
largescal
phase
iii
clusterrandom
efficaci
trial
particular
advers
event
report
addit
interim
analysi
vaccin
elicit
high
level
efficaci
evdexpos
particip
incid
postvaccin
fever
studi
yet
report
summari
candid
vaccin
evd
progress
phase
studi
respons
outbreak
demonstr
accept
safeti
profil
therefor
describ
magnitud
characterist
vaccineinduc
immun
next
scientif
aim
bind
assay
particularli
enzymelink
immunosorb
assay
elisa
commonli
use
assess
quantiti
antigenspecif
antibodi
induc
postvaccin
addit
use
measur
qualit
aspect
humor
immun
respons
isotyp
profil
vitro
avid
ebolaviru
outbreak
occur
sporad
previous
consid
limit
size
enabl
assess
vaccin
efficaci
prior
regulatori
approv
usa
food
drug
administr
fda
introduc
anim
rule
enabl
data
preclin
trial
use
demonstr
efficaci
human
trial
possibl
altern
licens
rout
drug
vaccin
highli
lethal
diseas
despit
wide
use
elisa
assay
measur
antiglycoprotein
igg
respons
major
phase
studi
use
array
differ
antibodi
bind
assay
assess
quantiti
qualiti
antigenspecif
antibodi
respons
induc
vaccin
tabl
use
differ
assay
conduct
differ
laboratori
follow
differ
protocol
hinder
comparison
humor
immunogen
induc
differ
vaccin
candid
key
differ
assay
affect
compar
result
includ
use
glycoprotein
differ
strain
zair
ebola
viru
kikwit
makona
mayinga
use
whole
virion
recombin
protein
use
differ
readout
unit
central
standard
assay
readili
avail
biolog
standard
rang
emerg
pathogen
would
use
tool
aid
decis
maker
choos
promis
candid
take
forward
test
rapid
deploy
outbreak
refer
reagent
antiebov
igg
establish
expert
committe
biolog
standardis
ecb
use
refer
standard
humor
immunoassay
includ
neutral
elisa
ebola
viru
freeli
avail
nation
institut
biolog
standard
control
nibsc
uk
facilit
retrospect
comparison
respons
differ
trial
aid
comparison
immunogen
across
trial
sampl
recent
phase
trial
mvabn
filo
run
larg
number
assay
correl
analys
conduct
tabl
lack
correl
assay
may
indic
measur
differ
aspect
humor
immun
respons
may
therefor
correl
differ
protect
exampl
competit
elisa
use
ewer
cowork
correl
neutral
titr
live
ebola
viru
mayinga
strain
sever
glycoprotein
elisa
competit
elisa
measur
abil
antiebov
antibodi
sampl
compet
monoclon
ebov
antibodi
mab
therefor
detect
activ
singl
gp
epitop
lack
correl
neutral
titr
may
indic
antibodi
bind
epitop
nonneutr
protect
observ
mab
use
mab
cocktail
nhp
model
confer
altern
mechan
mani
bind
assay
use
phase
trial
correl
strongli
particular
use
standard
glycoprotein
elisa
pseudotyp
lentiviru
assay
correl
strongli
neutral
titr
live
ebola
viru
assay
avoid
need
work
high
contain
level
may
use
indic
presenc
antibodi
neutral
activ
preclin
nhp
model
igg
respons
immun
ebola
viru
vaccin
measur
use
elisa
gp
protect
lethal
challeng
predict
titr
greater
titr
around
predict
surviv
time
outbreak
one
measur
avail
estim
potenti
efficaci
candid
vaccin
sever
phase
clinic
studi
use
assay
facilit
comparison
interim
analysi
phase
iii
ring
vaccin
studi
rvsvzebov
guinea
estim
vaccin
efficaci
trial
immunogen
data
publish
trial
due
logist
difficulti
associ
collect
biolog
sampl
therefor
unclear
compon
immun
respons
vaccin
mediat
protect
effect
howev
phase
trial
vaccin
dose
usa
induc
igg
zairemayinga
gp
geometr
mean
titr
gmt
ci
day
postvaccin
probabl
higher
level
achiev
day
postvaccin
time
new
case
observ
rvsvzebov
ring
vaccin
trial
gmt
well
titr
requir
protect
nonhuman
primat
experiment
model
zebov
given
dose
viral
particl
vp
induc
titr
compar
induc
rvsvzebov
day
gmt
ci
us
adult
malian
adult
peak
titr
boost
mva
zebov
significantli
increas
although
use
differ
assay
summar
tabl
limit
comparison
immunogen
across
clinic
trial
still
much
learnt
comparison
group
within
trial
desanti
cowork
show
limit
dose
effect
antigp
igg
titr
assess
elisa
ebov
test
vp
vp
peak
titr
respons
rate
similar
two
group
peak
day
indic
durabl
also
compar
howev
trial
ledgerwood
et
al
compar
mixtur
zebov
sudv
ratio
vp
indic
higher
dose
induc
significantli
higher
geometr
mean
elisa
titr
antigp
igg
despit
similar
respons
rate
trial
volunt
high
dose
group
develop
antibodi
respons
vaccin
strain
zair
glycoprotein
mayinga
develop
respons
glycoprotein
outbreak
strain
guinea
addit
respons
rate
induc
vaccin
strain
sudan
glycoprotein
high
dose
group
low
dose
group
lower
zair
despit
receiv
dose
may
reflect
differ
sensit
two
assay
rapid
develop
multipl
vaccin
candid
parallel
recent
outbreak
highlight
need
standard
assay
measur
humor
immunogen
correl
respons
measur
differ
assay
inclus
refer
standard
aid
comparison
qualiti
quantiti
humor
respons
induc
differ
vaccin
candid
support
decis
take
forward
develop
lack
discrimin
neutral
nonneutr
antibodi
level
elisa
output
nonneutr
antibodi
play
import
role
curb
infect
also
concert
effort
identifi
neutral
antibodi
nab
key
determin
infect
control
mani
diseas
set
present
data
suggest
neutral
nonneutr
antibodi
import
evd
set
measur
aspect
humor
immun
elisa
neutral
assay
inform
viru
neutral
assay
eg
fluoresc
antibodi
viru
neutral
favn
assay
plaqu
reduct
neutral
test
prnt
measur
nab
respons
howev
prerequisit
highli
train
staff
access
contain
level
facil
work
ebolaviru
wide
avail
exampl
singl
laboratori
base
marburg
analys
sampl
phase
studi
addit
assay
necessit
care
consid
plan
result
lowthroughput
expens
timeconsum
assay
prevent
accident
exposur
circumv
restrict
assay
use
nonpathogen
replicationdefect
pseudotyp
virus
pv
develop
facilit
studi
highli
pathogen
virus
standard
contain
level
laboratori
pv
chimer
virion
compris
structur
enzymat
core
one
viru
heterolog
envelop
protein
eg
ebov
glycoprotein
typic
retrovirus
lentivirus
gammaretrovirus
rhabdovirus
vesicular
stomat
viru
use
pseudotyp
core
transduct
permiss
target
cell
facilit
genom
transfer
subsequ
report
protein
express
allow
quantifi
readout
transduct
produc
quantit
readout
howev
preincub
pv
nab
bind
envelop
protein
inhibit
cell
entri
result
lower
level
quantifi
report
protein
express
mani
pv
assay
develop
assess
neutral
antibodi
toward
filoviru
famili
member
inde
number
assay
use
collabor
studi
establish
refer
standard
antibodi
ebola
viru
data
studi
suggest
pv
assay
offer
obviou
improv
live
nab
assay
may
gener
fals
posit
new
filoviru
pv
assay
requir
stringent
standard
use
valid
neg
posit
control
limit
number
pv
assay
use
recent
clinic
trial
may
reflect
urgent
need
rank
vaccin
modal
ebola
outbreak
concert
effort
screen
use
live
neutral
assay
howev
number
inform
comparison
live
ebov
neutral
pv
neutral
recent
clinic
trial
help
establish
use
earli
applic
assay
screen
rank
vaccin
candid
tabl
neutral
antibodi
measur
singleround
infect
assay
ebov
gppseudotyp
lentivirus
measur
follow
singl
im
vaccin
phase
clinic
trial
vaccin
express
ebov
gp
antigen
except
one
subject
sera
inhibit
viru
entri
team
also
use
ebov
marv
gppseudotyp
lentivirus
measur
neutral
antibodi
activ
dna
vaccin
signific
marburg
viru
neutral
activ
observ
follow
dna
vaccin
lowlevel
ebov
neutral
activ
measur
follow
fourth
dna
vaccin
data
help
evalu
vaccin
regimen
identifi
vaccin
regimen
yield
improv
neutral
respons
recent
phase
clinic
studi
oxford
seven
differ
assay
humor
immun
undertaken
sampl
vaccine
provid
uniqu
opportun
assess
relationship
differ
measur
immunogen
tabl
volunt
administ
singl
dose
ebov
gp
subset
administ
booster
dose
mva
strain
encod
ebola
viru
glycoprotein
two
assay
use
measur
neutral
antibodi
direct
neutral
live
ebov
mayinga
strain
pseudotyp
lentiviru
express
glycoprotein
mayinga
strain
readout
inhibitori
concentr
neutral
antibodi
titr
live
ebov
mayinga
strain
low
day
dose
level
significantli
higher
day
mva
boost
vaccin
lowlevel
inhibit
infect
observ
postprim
use
pseudotyp
lentiviru
express
gp
mayinga
strain
ebov
level
nab
increas
significantli
postboost
importantli
neutral
antibodi
titr
live
ebov
pv
assay
correl
posit
r
p
titr
measur
elisa
live
ebov
mayinga
strain
neutral
assay
r
p
nab
also
assay
vaccine
receiv
rvsvzebov
use
vsv
pseudovirion
express
glycoprotein
ebov
kikwit
strain
live
neutral
assay
infecti
ebov
isol
mayinga
nab
detect
vaccine
receiv
littl
pfu
rvsvzebov
two
nab
assay
show
signific
increas
neutral
antibodi
dose
rvsvzebov
rang
pfu
pfu
strong
correl
antibodi
titr
assess
glycoprotein
elisa
vsv
pseudovirion
live
viru
neutral
titr
demonstr
signific
correl
vaccin
dose
neutral
antibodi
titr
also
identifi
use
vsv
pseudovirion
correl
observ
use
whole
virion
infecti
ebola
viru
may
reflect
lower
sensit
thu
weaker
discriminatori
capac
whole
virion
infecti
ebola
viru
assay
increas
interest
measur
nab
post
vaccin
toward
highli
pathogen
virus
suggest
increas
sensit
establish
standard
pv
assay
underpin
continu
develop
use
pv
assay
broadspectrum
detect
postvaccin
humor
respons
baiz
cowork
analys
sampl
patient
two
larg
outbreak
gabon
compar
cellular
humor
respons
survivor
patient
succumb
infect
determin
rel
contribut
differ
immun
paramet
evd
outcom
surviv
associ
earli
rapid
rise
igg
direct
mainli
toward
viral
nucleoprotein
addit
activ
cell
upregul
fasl
perforin
cell
specif
ebola
viru
nucleoprotein
also
associ
protect
mous
model
evd
cell
induc
zebov
gp
vaccin
nhp
afford
protect
lethal
challeng
model
vivo
deplet
cell
use
monoclon
antibodi
abrog
protect
four
five
nhp
wherea
passiv
transfer
igg
induc
protect
therefor
enumer
antigenspecif
cell
respons
candid
ebola
vaccin
import
aspect
immunolog
outcom
studi
human
mani
clinic
trial
replicationdefici
viral
vector
vaccin
report
cell
respons
measur
flow
cytometri
intracellular
cytokin
stain
ic
use
pool
peptid
span
glycoprotein
stimul
peripher
blood
mononuclear
cell
pbmc
comparison
across
studi
imped
differ
sampl
type
use
freshli
isol
versu
cryopreserv
pbmc
variat
denomin
use
report
respons
memori
versu
total
differ
data
analysi
methodolog
group
also
report
glycoproteinspecif
cell
respons
elispot
addit
ic
howev
differ
respons
fresh
frozen
pbmc
make
broad
comparison
difficult
although
comparison
trial
unreli
limit
comparison
possibl
eg
use
fresh
pbmc
elispot
vector
encod
ebov
gp
induc
antigenspecif
cell
respons
similar
magnitud
vaccin
regimen
vector
encod
ebov
sudv
gp
mix
respond
frequenc
magnitud
respons
report
howev
respond
frequenc
mixtur
vector
similar
observ
ebov
gp
alon
howev
possibl
importantli
comparison
group
within
studi
yield
interest
insight
use
viral
vector
broader
relev
beyond
ebola
viru
vaccin
exampl
larg
trial
oxford
compar
mvabn
filo
prime
zebov
boost
demonstr
first
time
human
prime
mva
vector
boost
adenoviru
least
effect
induc
antigenspecif
cell
convent
deliveri
adprim
follow
mva
boost
surprisingli
rvsvzebov
vaccin
todat
vaccin
field
efficaci
assess
yet
describ
cellinduc
capabl
cynomolog
macaqu
immun
rvsvzebov
cytokinesecret
cell
stimul
gp
peptid
detect
immun
howev
respons
detect
vaccin
anim
ebov
challeng
suggest
immun
may
prime
respons
cell
respons
rvsvzebov
assess
phase
studi
absenc
cmi
would
interest
vaccin
develop
field
mainten
humor
immun
obvious
depend
cmi
yet
failur
detect
respons
peripher
surpris
interest
immunologist
perspect
immedi
respons
evd
outbreak
west
africa
begin
wind
scientist
polici
maker
involv
vaccin
develop
reflect
progress
made
field
difficult
time
well
implic
futur
outbreak
notabl
gain
success
achiev
includ
rapid
approv
complet
clinic
studi
exist
newli
produc
candid
evd
vaccin
underpin
capac
ethic
regulatori
author
expedit
approv
context
public
health
emerg
public
data
studi
undertaken
respons
outbreak
also
rapid
mani
journal
set
asid
polici
relat
prior
disclosur
data
allow
data
share
bodi
without
prejudic
futur
public
vaccin
evd
exist
partli
due
north
american
biodefens
prioriti
rather
plan
strategi
prepared
rapid
respons
emerg
pathogen
efficaci
rvsvzebov
vaccin
phase
iii
trial
guinea
context
primarili
iggmedi
respons
suggest
efficaci
evd
vaccin
may
compar
easi
produc
compar
effort
gener
vaccin
diseas
malaria
hiv
tuberculosi
indic
nhp
vaccin
model
ebov
gp
analysi
immun
respons
evd
survivor
indic
cell
compon
would
prerequisit
effect
evd
vaccin
yet
rvsvzebov
vaccin
may
induc
signific
cmi
compon
base
preclin
data
addit
consider
passiv
transfer
ebolaspecif
antibodi
fail
protect
nhp
lethal
ebola
viru
challeng
indic
antibodi
titr
may
nonmechanist
correl
protect
qualit
aspect
antibodi
respons
andor
cellular
immun
readili
measur
also
play
key
role
protect
like
mechan
protect
protect
level
particular
immun
compon
may
well
differ
experiment
model
nhp
challeng
manner
may
accur
reflect
natur
exposur
human
expos
natur
infect
highlight
import
overreli
immunolog
correl
deriv
preclin
test
clearli
differ
vaccin
deliveri
method
induc
qualit
differ
immun
respons
induct
longlast
humor
immun
absenc
cell
seem
unlik
abil
primeboost
regimen
induc
durabl
cmi
humor
immun
may
desir
longev
protect
decemb
held
workshop
priorit
pathogen
gener
list
seven
diseas
requir
urgent
r
three
diseas
requir
action
soon
possibl
list
encompass
emerg
diseas
potenti
gener
public
health
emerg
insuffici
prevent
cur
solut
exist
crimean
congo
haemorrhag
fever
cchf
evd
marburg
haemorrhag
fever
lassa
fever
mer
sar
nipah
rift
valley
fever
viru
identifi
prioriti
emerg
pathogen
research
zika
chikungunya
sever
fever
thrombocytopaenia
syndrom
sft
determin
seriou
necessit
action
soon
possibl
evd
outbreak
focus
attent
emerg
pathogen
shift
place
public
conscious
theoret
emerg
tangibl
threat
global
health
vaccin
develop
must
think
term
address
emerg
pathogen
entireti
rather
collect
individu
highli
virul
pathogen
end
recent
outbreak
yield
valuabl
insight
firstli
context
ongo
outbreak
singl
dose
viral
vector
vaccin
could
suffici
induc
least
shortterm
protect
immun
filovirus
use
protect
frontlin
healthcar
worker
commun
therebi
reduc
spread
epidem
earliest
stage
outbreak
pathogen
readili
identifi
singl
dose
recombin
adenovir
vsv
vector
may
suffic
outbreak
control
howev
counter
threat
infecti
outbreak
may
emerg
unpredict
largescal
prophylact
immun
healthcar
worker
would
use
first
line
defenc
singledos
multival
vaccin
encod
antigen
sever
put
emerg
pathogen
could
particularli
valuabl
scenario
exampl
recombin
mva
would
suit
purpos
given
potenti
insert
variou
foreign
gene
numer
site
genom
number
promot
contrast
adenoviru
vector
limit
clone
capac
carri
foreign
gene
immun
could
subsequ
boost
adenovir
vector
express
specif
transgen
outbreak
pathogen
identifi
studi
evd
vaccin
regimen
employ
mva
prime
vector
boost
demonstr
feasibl
approach
specul
group
emerg
pathogen
accord
geograph
incid
may
one
strategi
determin
compon
multival
vaccin
exampl
potenti
strategi
design
vaccin
use
approach
suggest
figur
almost
current
evd
vaccin
candid
use
gp
antigen
due
abund
express
surfac
viru
extens
preclin
data
reflect
promis
immunogen
efficaci
challeng
target
antigen
studi
patient
evd
two
outbreak
gabon
reveal
survivor
igg
respons
larg
direct
nucleoprotein
observ
made
small
studi
evd
case
usa
character
immun
respons
natur
ebolaviru
infect
also
reveal
exposur
induc
crossreact
antibodi
capabl
neutral
multipl
ebolaviru
speci
studi
natur
acquir
immun
survivor
bdbv
outbreak
uganda
demonstr
first
time
potent
neutral
antibodi
glycan
cap
gp
could
inhibit
sever
ebolavirus
includ
sudv
protect
guinea
pig
heterolog
challeng
ebov
may
offer
insight
immunogen
design
confer
heterosubtyp
immun
across
multipl
ebolavirus
given
larg
number
survivor
outbreak
signific
effort
made
character
immun
afford
protect
face
infect
highli
lethal
pathogen
help
inform
antigen
select
futur
vaccin
advanc
understand
postevd
immunolog
whether
vaccin
need
emul
natur
occur
mechan
remain
seen
observ
critic
import
help
advanc
field
closer
examin
prioriti
pathogen
highlight
may
facilit
develop
broadspectrum
vaccin
virus
small
genom
obviou
vaccin
candid
antigen
preclin
data
highli
indic
set
data
one
health
approach
combin
human
anim
environment
consider
address
global
health
challeng
invalu
exampl
immunogen
data
deriv
studi
zoonot
reservoir
appli
vaccin
develop
furthermor
studi
famili
virus
use
technolog
advanc
cryoelectron
microscopi
b
cell
clone
antibodi
repertoir
sequenc
may
yield
novel
target
may
effect
tackl
emerg
pathogen
phylogenet
relat
virus
share
receptorbind
domain
epitop
within
envelop
protein
may
well
share
therapeut
vaccin
target
discuss
great
effort
made
character
magnitud
neutral
antibodi
titr
induc
vaccin
yet
detail
entryblock
mechan
yet
fulli
util
vaccinologist
detail
understand
interact
yield
numer
opportun
vaccin
diseas
includ
malaria
hiv
indepth
understand
process
associ
inhibit
receptor
bind
conform
rearrang
glycoprotein
requir
viral
fusion
could
possibl
identifi
ubiquit
target
mab
prevent
infect
multipl
viru
speci
exampl
entri
filovirus
mammalian
cell
util
endosom
receptor
niemannpick
protein
present
obviou
target
inhibit
viru
entri
outbreak
highli
pathogen
diseas
evd
devast
popul
affect
alway
focu
attent
control
strategi
prevent
futur
occurr
wide
acknowledg
global
public
health
respons
tragic
slow
begin
immunologist
vaccinologist
valuabl
opportun
learn
much
possibl
disast
well
probe
vaccineinduc
respons
mani
clinic
trial
taken
place
detail
character
natur
acquir
immun
survivor
evd
asymptomat
ebov
iggseroposit
member
commun
system
compil
previou
data
gabon
illustr
substanti
proport
rural
popul
evid
ebovspecif
immun
collect
respons
assimil
inform
outbreak
gener
order
best
place
next
epidem
come
respond
effect
robustli
curb
outbreak
infanc
